Omnicell (NASDAQ:OMCL) Downgraded to "Hold" Rating by StockNews.com

Omnicell (NASDAQ:OMCL - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a report released on Friday.

OMCL has been the topic of a number of other research reports. Benchmark reaffirmed a "buy" rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company raised their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a research note on Monday, October 14th. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. Finally, Bank of America restated a "neutral" rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $50.83.

Omnicell Price Performance

Shares of OMCL traded down $0.93 during mid-day trading on Friday, reaching $45.67. 393,731 shares of the company's stock were exchanged, compared to its average volume of 526,537. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The business's fifty day simple moving average is $44.19 and its 200-day simple moving average is $36.70. The stock has a market capitalization of $2.12 billion, a PE ratio of -117.10, a price-to-earnings-growth ratio of 46.03 and a beta of 0.81.

Institutional Trading of Omnicell

A number of hedge funds have recently bought and sold shares of OMCL. GAMMA Investing LLC lifted its holdings in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after buying an additional 553 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock valued at $38,000 after acquiring an additional 1,000 shares during the period. 1620 Investment Advisors Inc. boosted its stake in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after buying an additional 1,542 shares in the last quarter. EntryPoint Capital LLC boosted its holdings in Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company's stock valued at $72,000 after purchasing an additional 1,345 shares in the last quarter. Finally, CWM LLC grew its position in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company's stock valued at $83,000 after acquiring an additional 1,236 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.